2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
June 30th, 2025
Version: 2
Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
cancer biology
biorxiv

NK cell co-localization with epithelial cells in pancreatic cancer is influenced by fibroblasts and ECM components

Malchiodi, Z. X.Open in Google Scholar•Lekan, A. A.Open in Google Scholar•Suter, R. K.Open in Google Scholar•Deshpande, A.Open in Google Scholar•Peran, I.Open in Google Scholar•Harris, B. T.Open in Google Scholar•Duttargi, A.Open in Google Scholar•Chien, M.-J.Open in Google Scholar•Hariharan, S.Open in Google Scholar•Wetherill, L.Open in Google Scholaret al.

Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive and common type of pancreatic cancer. PDAC has a dense, fibrotic tumor microenvironment (TME) that restricts immune cell infiltration and contributes to poor immunotherapy responses. While T cell-based therapies have been largely ineffective, natural killer (NK) cells-which kill tumor cells without requiring MHC recognition-offer a promising alternative. However, their role in the PDAC TME remains poorly understood. Here, we show that NK cells are present, active, and spatially associated with malignant epithelial cells in human PDAC. Using cytometry by time-of-flight (CyTOF) in murine PDAC, imaging mass cytometry (IMC) in human tumors, and CellChat analysis of a human PDAC scRNAseq dataset, we found that NK cells interact with extracellular matrix (ECM) components via CD44. Fibroblast-rich, desmoplastic regions appear to limit NK cell infiltration. In vitro 2D and 3D assays revealed that CD44 neutralization significantly enhances NK cell matrix invasion. These findings highlight the underappreciated presence and tumor cell-proximal localization of NK cells in PDAC and identify ECM-CD44 interactions as a barrier to their infiltration. Targeting these interactions may enhance NK cell-based immunotherapy in PDAC.

Similar Papers

biorxiv
Mon Jun 30 2025
Decoding Breast Cancer Heterogeneity via Multi-Omics Integration and Language Model-Based Interpretation
We present a novel pipeline combining Multi-Omics Factor Analysis (MOFA) and fine-tuned Large Language Models (LLMs) to predict breast cancer subtypes using proteomics, DNA methylation, and RNA-Seq data. Breast cancer is a heterogeneous disease characterized by diverse molecular alterations across multiple biological layers, necessitating integrative approaches for accurate subtype classification....
Yasrab, R.
•
Agrawal, R.
•
Saber-Ayad, M.
•
El-Hadidi, M.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Mon Jun 30 2025
Vinorelbine enhances the efficacy of GM-CSF-armed oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma
Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agen...
Drymiotou, S.
•
Queval, C. J.
•
Tyson, K. E.
•
Sheach, L. A.
...•
Way, M.
biorxiv
Mon Jun 30 2025
Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunity
Regulatory T cells (Tregs) infiltrate most tumors, yet whether they suppress immune responses directly within tumor tissues is untested. We used intratumoral (IT) delivery of diphtheria toxin (DT) in Foxp3DTR mice to deplete IT Tregs while leaving peripheral Tregs intact. IT delivery of DT reduced Treg frequencies in the tumor, which promoted potent tumor control without autoimmunity. Interestingl...
Bockman, A.
•
Gittins, B.
•
Zhang, C.
•
Hung, J.
...•
DuPage, M.
biorxiv
Mon Jun 30 2025
CD47 blockade enhances immunoradiotherapy response in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promi...
Monther, A.
•
Al-Msari, R.
•
Saddawi-Konefka, R.
•
Fassardi, S.
...•
Califano, J.
biorxiv
Mon Jun 30 2025
Targeting breast cancer senescence in 3D models of bone metastasis
Chemotherapeutic treatment of breast cancer with Doxorubicin can induce tumor and stromal cell senescence leading to therapy-resistance. Senescence-associated secretory phenotype (SASP) promotes secretion of pro-inflammatory and tumorigenic factors causing systemic inflammation. Combined, this can result in immune suppression, tumor growth and secondary spread of cancer. Targeting and removing sen...
Hamburger, E. C. B.
•
Mohseni Garakani, M.
•
Alfaisali, S.
•
Ouellet, J. A.
...•
Rosenzweig, D. H.
biorxiv
Mon Jun 30 2025
Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of Resistance
Osimertinib (Osi) resistance remains a significant challenge in EGFR mutant non-small-cell lung cancer (NSCLC). This study investigates the metabolic reprogramming associated with Osi resistance, identifying key metabolic vulnerabilities that may be targeted for therapeutic intervention. Employing the EGFR-mutant H1975 parental (Par) cell line and its Osi-resistant (OsiR) counterpart, we integrate...
Maroni, G.
•
Cabrera San Millan, E.
•
Mercatelli, R.
•
Chiodi, A.
...•
Levantini, E.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Sun Jun 29 2025
Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia
Riboflavin is a diet-derived vitamin in higher organisms that serves as a precursor for flavin mononucleotide and flavin adenine dinucleotide, key cofactors that participate in oxidoreductase reactions. Here, using proteomic, metabolomic and functional genomics approaches, we describe a specific riboflavin dependency in acute myeloid leukemia and demonstrate that, in addition to energy production ...
Bjelosevic, S.
•
Fauth, R.
•
Do, B. T.
•
Alexe, G.
...•
Stegmaier, K.